There are 49 compatible spacers
The use of each medicine included in Right Breathe has been considered in relation to international, national, and regional prescribing pathways. The pathway points at which this medicine is considered a viable prescribing option are included below. If you wish to view the entire pathway, click on its heading, from where you can also access all the prescribing options for each pathway and each pathway point.
Detailed prescribing information is provided below. This content has not been generated by the RightBreathe team, but has been integrated from a 3rd party solution: Multilex (provided by FirstDataBank). Use of this prescribing content is subject to the FirstDataBank disclaimer, which is set out in the "About" section of RightBreathe.
As RightBreathe is a bespoke decision support tool, it covers each and every individual known inhaler option on the UK market to a high level of specificity. Multilex, as a more general resource, does not offer the same level of specificity. There are therefore a small number of medicines for which there are discrepancies between RightBreathe and Multilex content, most notably in relation to licensed particulars and associated licensed doses.
Given the high level of specificity the RightBreathe team work to, details of the individual inhaler licence are most likely to be summarised accurately in the content provided at the top of this page, rather than in the Multilex content below. Where there is ambiguity, users may also wish to refer to individual summaries of product characteristics prior to prescribing.
Type | Age Range | Dose | Licensed |
---|---|---|---|
Maintenance | From 12 years to 18 years | 1 actuation - FOUR times a DAY - inhalation - using a metered dose device | |
Maintenance | From 18 years | 1 actuation - FOUR times a DAY - inhalation - using a metered dose device | |
Maintenance | From 1 month to 6 years | 1 actuation - THREE times a DAY - inhalation - using a metered dose device | |
Maintenance | From 6 years to 12 years | 1 actuation - THREE times a DAY - inhalation - using a metered dose device | |
Maintenance | From 12 years to 18 years | 1 actuation - THREE times a DAY - inhalation - using a metered dose device | |
Maintenance | From 18 years | 1 actuation - THREE times a DAY - inhalation - using a metered dose device | |
Maintenance | From 12 years to 18 years | 1 actuation - THREE to FOUR times a DAY - inhalation - using a metered dose device | |
Maintenance | From 18 years | 1 actuation - THREE to FOUR times a DAY - inhalation - using a metered dose device | |
Maintenance | From 6 years to 12 years | 1 to 2 actuations - THREE times a DAY - inhalation - using a metered dose device | |
Maintenance | From 12 years to 18 years | 1 to 2 actuations - THREE to FOUR times a DAY - inhalation - using a metered dose device | |
Maintenance | From 18 years | 1 to 2 actuations - THREE to FOUR times a DAY - inhalation - using a metered dose device | |
Maintenance | From 12 years to 18 years | 2 actuations - FOUR times a DAY - inhalation - using a metered dose device | |
Maintenance | From 18 years | 2 actuations - FOUR times a DAY - inhalation - using a metered dose device | |
Maintenance | From 6 years to 12 years | 2 actuations - THREE times a DAY - inhalation - using a metered dose device | |
Maintenance | From 12 years to 18 years | 2 actuations - THREE times a DAY - inhalation - using a metered dose device | |
Maintenance | From 18 years | 2 actuations - THREE times a DAY - inhalation - using a metered dose device | |
Maintenance | From 12 years to 18 years | 2 actuations - THREE to FOUR times a DAY - inhalation - using a metered dose device | |
Maintenance | From 18 years | 2 actuations - THREE to FOUR times a DAY - inhalation - using a metered dose device |
Type | Age Range | Dose | Licensed |
---|---|---|---|
Maintenance | From 12 years to 18 years | 1 actuation - FOUR times a DAY - inhalation - using a metered dose device | |
Maintenance | From 18 years | 1 actuation - FOUR times a DAY - inhalation - using a metered dose device | |
Maintenance | From 1 month to 6 years | 1 actuation - THREE times a DAY - inhalation - using a metered dose device | |
Maintenance | From 6 years to 12 years | 1 actuation - THREE times a DAY - inhalation - using a metered dose device | |
Maintenance | From 12 years to 18 years | 1 actuation - THREE times a DAY - inhalation - using a metered dose device | |
Maintenance | From 18 years | 1 actuation - THREE times a DAY - inhalation - using a metered dose device | |
Maintenance | From 12 years to 18 years | 1 actuation - THREE to FOUR times a DAY - inhalation - using a metered dose device | |
Maintenance | From 18 years | 1 actuation - THREE to FOUR times a DAY - inhalation - using a metered dose device | |
Maintenance | From 6 years to 12 years | 1 to 2 actuations - THREE times a DAY - inhalation - using a metered dose device | |
Maintenance | From 12 years to 18 years | 1 to 2 actuations - THREE to FOUR times a DAY - inhalation - using a metered dose device | |
Maintenance | From 18 years | 1 to 2 actuations - THREE to FOUR times a DAY - inhalation - using a metered dose device | |
Maintenance | From 12 years to 18 years | 2 actuations - FOUR times a DAY - inhalation - using a metered dose device | |
Maintenance | From 18 years | 2 actuations - FOUR times a DAY - inhalation - using a metered dose device | |
Maintenance | From 6 years to 12 years | 2 actuations - THREE times a DAY - inhalation - using a metered dose device | |
Maintenance | From 12 years to 18 years | 2 actuations - THREE times a DAY - inhalation - using a metered dose device | |
Maintenance | From 18 years | 2 actuations - THREE times a DAY - inhalation - using a metered dose device | |
Maintenance | From 12 years to 18 years | 2 actuations - THREE to FOUR times a DAY - inhalation - using a metered dose device | |
Maintenance | From 18 years | 2 actuations - THREE to FOUR times a DAY - inhalation - using a metered dose device |
With | Risk | Severity |
---|---|---|
METHACHOLINE | Methacholine effect reduced; review dosing, see product literature | Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk. |
AMANTADINE | Antimuscarinic side effects may be increased | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
ANTIHISTAMINES - SEDATIVE | Antimuscarinic side effects may be increased | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
CODEINE | Antimuscarinic side effects may be increased/risk of paralytic ileus | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
CYCLIZINE (IN COMBINATION WITH STRONG OPIOIDS) | Antimuscarinic side effects may be increased | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
DISOPYRAMIDE | Antimuscarinic side effects may be increased | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
MAOIS | Antimuscarinic side effects may be increased | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
NEFOPAM | Antimuscarinic side effects may be increased | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
TRICYCLIC ANTIDEPRESSANTS | Antimuscarinic side effects may be increased | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
TRICYCLIC ANTIDEPRESSANTS AND PHENOTHIAZINES (COMBINED PRODUCT) | Antimuscarinic side effects may be increased | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
(OXYPERTINE) | Antimuscarinic side effects may be increased | Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient. |
(REMOXIPRIDE) | Antimuscarinic side effects may be increased | Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient. |
(TRIFLUPERIDOL) | Antimuscarinic side effects may be increased | Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient. |
(ZOTEPINE) | Antimuscarinic side effects may be increased | Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient. |
AMISULPRIDE | Antimuscarinic side effects may be increased | Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient. |
ARIPIPRAZOLE | Antimuscarinic side effects may be increased | Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient. |
BENPERIDOL | Antimuscarinic side effects may be increased | Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient. |
CLOZAPINE | Antimuscarinic side effects may be increased | Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient. |
DROPERIDOL | Antimuscarinic side effects may be increased | Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient. |
FLUSPIRILENE | Antimuscarinic side effects may be increased | Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient. |
HALOPERIDOL | Antimuscarinic side effects may be increased | Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient. |
LOXAPINE (INHALED) | Antimuscarinic side effects may be increased | Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient. |
LOXAPINE (ORAL) | Antimuscarinic side effects may be increased | Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient. |
MEMANTINE | effect may be increased by | Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient. |
OLANZAPINE | Antimuscarinic side effects may be increased | Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient. |
PALIPERIDONE | Antimuscarinic side effects may be increased | Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient. |
PHENOTHIAZINES | Antimuscarinic side effects may be increased | Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient. |
PIMOZIDE | Antimuscarinic side effects may be increased | Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient. |
QUETIAPINE | Antimuscarinic side effects may be increased | Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient. |
SERTINDOLE | Antimuscarinic side effects may be increased | Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient. |
SULPIRIDE | Antimuscarinic side effects may be increased | Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient. |
ZIPRASIDONE | Antimuscarinic side effects may be increased | Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient. |